Amedeo Smart

Free Medical Literature Service

 

Amedeo

Gynecology
  Free Subscription

Articles published in
Eur J Cancer
    November 2024
  1. MATIAS-GUIU X, Lax S, Raspollini MR, Palacios J, et al
    FIGO 2023 staging for endometrial cancer, when, if it is not now?
    Eur J Cancer. 2024;213:115115.
    >> Share

    October 2024
  2. WENZEL HHB, Schnack TH, Van der Aa MA, Jensen PT, et al
    Risk factors for lymph node metastasis in women with FIGO 2018 IA cervical cancer with a horizontal spread of > 7 mm.
    Eur J Cancer. 2024;212:115063.
    >> Share

  3. GIANNOPOULOS S, Naeem S, Nasioudis D, Gossner G, et al
    Value of surgical lymph node assessment for patients with vulvar melanoma.
    Eur J Cancer. 2024;210:114303.
    >> Share

    September 2024
  4. BIZZARRI N, Querleu D, Ramirez PT, Dostalek L, et al
    Survival associated with the use of sentinel lymph node in addition to lymphadenectomy in early-stage cervical cancer treated with surgery alone: A sub-analysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study.
    Eur J Cancer. 2024;211:114310.
    >> Share

  5. VULSTEKE C, Chambers SK, Perez MJR, Chan JK, et al
    Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.
    Eur J Cancer. 2024;208:114157.
    >> Share

    August 2024
  6. BOLLINO M, Geppert B, Lonnerfors C, Masback A, et al
    Prevalence and size of pelvic sentinel lymph node metastases in endometrial cancer.
    Eur J Cancer. 2024;209:114265.
    >> Share

    July 2024
  7. FASCHING PA, Hack CC, Nabieva N, Maass N, et al
    Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.
    Eur J Cancer. 2024;209:114239.
    >> Share

  8. SOUTHWORTH E, Thomson JP, Croy I, Churchman M, et al
    Whole exome sequencing reveals diverse genomic relatedness between paired concurrent endometrial and ovarian carcinomas.
    Eur J Cancer. 2024;208:114205.
    >> Share

    May 2024
  9. ROMA C, Esposito Abate R, Sacco A, Califano D, et al
    Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
    Eur J Cancer. 2024;206:114127.
    >> Share

    April 2024
  10. BOLLINO M, Geppert B, Lonnerfors C, Persson J, et al
    A selective anatomically based lymph node sampling can replace a side specific pelvic lymphadenectomy in endometrial cancer with failed sentinel node mapping.
    Eur J Cancer. 2024;204:114049.
    >> Share

  11. GRAVBROT N, Weil CR, DeCesaris CM, Gaffney DK, et al
    Corrigendum to "Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer" Eur. J. Cancer (201) (April) 2024, 113913.
    Eur J Cancer. 2024 Apr 2:114017. doi: 10.1016/j.ejca.2024.114017.
    >> Share

    March 2024
  12. TUNINETTI V, Virano E, Salutari V, Ricotti A, et al
    Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
    Eur J Cancer. 2024;203:114039.
    >> Share

  13. BOIDOT R, Blum MGB, Wissler MP, Gottin C, et al
    Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer.
    Eur J Cancer. 2024;202:113978.
    >> Share

    February 2024
  14. GRAVBROT N, Weil CR, DeCesaris CM, Gaffney DK, et al
    Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer.
    Eur J Cancer. 2024;201:113913.
    >> Share

  15. TANAKA LF, Schoffer O, Schriefer D, Schauberger G, et al
    An audit of 1632 routinely collected cervical cancer screening smears from 398 women in Germany: Results from the TeQaZ Study.
    Eur J Cancer. 2024;201:113915.
    >> Share

  16. LINDEMANN K, Kildal W, Kleppe A, Tobin KAR, et al
    Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer.
    Eur J Cancer. 2024;200:113584.
    >> Share

    January 2024
  17. MATSUO K, Chen L, Neuman MK, Klar M, et al
    Low-grade endometrioid endometrial cancer with adnexal only metastasis: Evaluation of de-escalation of adjuvant therapy.
    Eur J Cancer. 2024;200:113533.
    >> Share

  18. YANG Z, Zhang Y, Zhuo L, Sun K, et al
    Prediction of prognosis and treatment response in ovarian cancer patients from histopathology images using graph deep learning: a multicenter retrospective study.
    Eur J Cancer. 2024;199:113532.
    >> Share

    November 2023
  19. NERO C, Bizzarri N, Di Berardino S, Sillano F, et al
    Sentinel-node biopsy in apparent early stage ovarian cancer: final results of a prospective multicentre study (SELLY).
    Eur J Cancer. 2023;196:113435.
    >> Share

    October 2023
  20. SAVOYE I, Silversmit G, Bourgeois J, De Gendt C, et al
    Association between hospital volume and outcomes in invasive ovarian cancer in Belgium: A population-based study.
    Eur J Cancer. 2023;195:113402.
    >> Share

  21. BIZZARRI N, Imterat M, Fruscio R, Giannarelli D, et al
    Lymph node staging in grade 1-2 endometrioid ovarian carcinoma apparently confined to the ovary: Is it worth?
    Eur J Cancer. 2023;195:113398.
    >> Share

  22. LEARY A, Oaknin A, Trigo JM, Moreno V, et al
    Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.
    Eur J Cancer. 2023;192:113259.
    >> Share

    September 2023
  23. VERGOTE I, Matias-Guiu X
    New FIGO 2023 endometrial cancer staging validation. Welcome to the first molecular classifiers and new pathological variables!
    Eur J Cancer. 2023 Sep 27:113318. doi: 10.1016/j.ejca.2023.113318.
    >> Share

  24. WOJTYLA C, Bertuccio P, Giermaziak W, Santucci C, et al
    European trends in ovarian cancer mortality, 1990-2020 and predictions to 2025.
    Eur J Cancer. 2023;194:113350.
    >> Share

  25. MATSUO K, Klar M, Song BB, Roman LD, et al
    Validation of the 2023 FIGO staging schema for advanced endometrial cancer.
    Eur J Cancer. 2023 Sep 21:113316. doi: 10.1016/j.ejca.2023.113316.
    >> Share

  26. PETRELLI F, Cavallone M, Dottorini L
    10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysis.
    Eur J Cancer. 2023;193:113322.
    >> Share

  27. SCHWAMEIS R, Fanfani F, Ebner C, Zimmermann N, et al
    Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - An international pooled analysis of three ESGO accredited centres.
    Eur J Cancer. 2023 Sep 1:113317. doi: 10.1016/j.ejca.2023.113317.
    >> Share

    August 2023
  28. DING S, Li H
    Re: A federated approach to identify women with early-stage cervical cancer at low risk of lymph node metastases.
    Eur J Cancer. 2023 Aug 1:112978. doi: 10.1016/j.ejca.2023.112978.
    >> Share

    July 2023
  29. HOWROYD LR, Cornell I, Benson C, Napolitano A, et al
    Pseudoprogression in patients with uterine leiomyosarcoma treated with first-line single-agent doxorubicin.
    Eur J Cancer. 2023;192:113261.
    >> Share

  30. CORBAUX P, You B, Glasspool RM, Yanaihara N, et al
    Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
    Eur J Cancer. 2023;191:112966.
    >> Share

    June 2023
  31. VALENZA C, Trapani D, Gandini S, Sposetti C, et al
    Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.
    Eur J Cancer. 2023;190:112944.
    >> Share

    May 2023
  32. GONZALEZ-MARTIN A, Pothuri B, Vergote I, Graybill W, et al
    Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
    Eur J Cancer. 2023 May 3:S0959-8049(23)00225-3. doi: 10.1016/j.ejca.2023.
    >> Share

    April 2023
  33. LOVERIX L, Vergote I, Busschaert P, Vanderstichele A, et al
    PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.
    Eur J Cancer. 2023;188:131-139.
    >> Share

  34. PETERS ITA, Marchetti C, De Palma A, Giannarelli D, et al
    Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era-Is it time for a new paradigm shift? A systematic review and meta-analysis.
    Eur J Cancer. 2023;187:77-86.
    >> Share

    March 2023
  35. LORUSSO D, Colombo N, Herraez AC, Santin AD, et al
    Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice.
    Eur J Cancer. 2023;186:172-184.
    >> Share

  36. PERRONE E, Capasso I, De Felice F, Giannarelli D, et al
    Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification.
    Eur J Cancer. 2023;186:98-112.
    >> Share

    February 2023
  37. WENZEL HHB, Hardie AN, Moncada-Torres A, Hogdall CK, et al
    A federated approach to identify women with early-stage cervical cancer at low risk of lymph node metastases.
    Eur J Cancer. 2023;185:61-68.
    >> Share

  38. WANG J, Cai L, Song Y, Sun T, et al
    Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study).
    Eur J Cancer. 2023;184:73-82.
    >> Share

    January 2023
  39. HERZOG TJ, Vergote I, Gomella LG, Milenkova T, et al
    Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    Eur J Cancer. 2023;179:136-146.
    >> Share

    December 2022
  40. CUEVA JF, Palacio I, Churruca C, Herrero A, et al
    Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme.
    Eur J Cancer. 2022;182:3-14.
    >> Share

  41. PANOUTSOPOULOU K, Magkou P, Dreyer T, Dorn J, et al
    tRNA-derived small RNA 3'U-tRF(ValCAC) promotes tumour migration and early progression in ovarian cancer.
    Eur J Cancer. 2022;180:134-145.
    >> Share

  42. SABATIER R, Rousseau F, Joly F, Cropet C, et al
    Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged >/=65 years from the PAOLA-1/ENGOT-ov25 trial.
    Eur J Cancer. 2022;181:42-52.
    >> Share

    September 2022
  43. XU B, Hu X, Li W, Sun T, et al
    Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4.
    Eur J Cancer. 2022;175:236-245.
    >> Share

  44. KREGTING LM, Olthof EMG, Breekveldt ECH, Aitken CA, et al
    Concurrent participation in breast, cervical, and colorectal cancer screening in the Netherlands.
    Eur J Cancer. 2022;175:180-186.
    >> Share

  45. GONZALEZ-MARTIN A, Desauw C, Heitz F, Cropet C, et al
    Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
    Eur J Cancer. 2022;174:221-231.
    >> Share

    August 2022
  46. GOLDRAT O, De Cooman M, Mailliez A, Delbaere A, et al
    Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study.
    Eur J Cancer. 2022;174:134-141.
    >> Share

    July 2022
  47. OAKNIN A, Monk BJ, Vergote I, Cristina de Melo A, et al
    EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.
    Eur J Cancer. 2022 Jul 31. pii: S0959-8049(22)00160.
    >> Share

  48. ANDERSON RA, Lambertini M, Hall PS, Wallace WH, et al
    Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy.
    Eur J Cancer. 2022;173:113-122.
    >> Share

  49. PASHANKAR F, Hanley K, Lockley M, Stoneham S, et al
    Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference.
    Eur J Cancer. 2022;173:59-70.
    >> Share

    June 2022
  50. PESENTI C, Beltrame L, Velle A, Fruscio R, et al
    Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis.
    Eur J Cancer. 2022;171:85-95.
    >> Share

  51. ALTUNDAG K
    Re: Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study: Higher visceral tumour burden and weak estrogen rece
    Eur J Cancer. 2022;171:43.
    >> Share

  52. HEIMOVAARA JH, Boere IA, de Haan J, van Calsteren K, et al
    Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands.
    Eur J Cancer. 2022;171:13-21.
    >> Share

    May 2022
  53. SIMON S, Francis KE, Dalrymple JE, Gebski V, et al
    Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2022;170:169-178.
    >> Share

  54. AMANT F, Nekljudova V, Maggen C, Seither F, et al
    Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.
    Eur J Cancer. 2022;170:54-63.
    >> Share

  55. PAULET L, Trecourt A, Leary A, Peron J, et al
    Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
    Eur J Cancer. 2022;166:87-99.
    >> Share

    April 2022
  56. AKESSON A, Adok C, Dahm-Kahler P
    Increased survival in non-endometrioid endometrial cancer after introducing lymphadenectomy and tailoring radiotherapy - A population-based cohort study.
    Eur J Cancer. 2022;169:54-63.
    >> Share

  57. MARTIN M, Zielinski C, Ruiz-Borrego M, Carrasco E, et al
    Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
    Eur J Cancer. 2022;168:12-24.
    >> Share

    March 2022
  58. CARTER TJ, George C, Harwood C, Nathan P, et al
    Melanoma in pregnancy: Diagnosis and management in early-stage and advanced disease.
    Eur J Cancer. 2022;166:240-253.
    >> Share

    December 2021
  59. DITTO A, De Cecco L, Paolini B, Alberti P, et al
    Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment.
    Eur J Cancer. 2021;161:55-63.
    >> Share

  60. JIANG F, Lin JK, Xiang Y, Xu ZF, et al
    The impact of pulmonary metastases on therapeutic response and prognosis in malignant gestational trophoblastic neoplasia patients: a retrospective cohort study.
    Eur J Cancer. 2021 Dec 13. pii: S0959-8049(21)01212.
    >> Share

    October 2021
  61. CIBULA D, Dostalek L, Jarkovsky J, Mom CH, et al
    The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer.
    Eur J Cancer. 2021;158:111-122.
    >> Share

    September 2021
  62. VERGOTE I, Ray-Coquard I, Anderson DM, Cantuaria G, et al
    Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
    Eur J Cancer. 2021;157:415-423.
    >> Share

  63. KANTIDAKIS G, Litiere S, Neven A, Vinches M, et al
    Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sar
    Eur J Cancer. 2021;154:253-268.
    >> Share

  64. HOVEN E, Fagerkvist K, Jahnukainen K, Ljungman L, et al
    Sexual dysfunction in young adult survivors of childhood cancer - A population-based study.
    Eur J Cancer. 2021;154:147-156.
    >> Share

    March 2021
  65. PUJOL P, Barberis M, Beer P, Friedman E, et al
    Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    Eur J Cancer. 2021;146:30-47.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016